Brief: Rubius Therapeutics Reports Q2 Results
31/08/2018 13:06
Aug 31 (Reuters) - Rubius Therapeutics Inc RUBY.O :
* RUBIUS THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL
RESULTS
* RUBIUS THERAPEUTICS INC QTRLY NET LOSS PER SHARE - BASIC &
DILUTED $3.33
* RUBIUS THERAPEUTICS INC - CASH, CASH EQUIVALENTS AND
MARKETABLE
SECURITIES TOTALED $181.7 MILLION AS OF JUNE 30 VERSUS $104.3
MILLION AS OF DEC 31, 2017
* RUBIUS THERAPEUTICS INC - EXPECTS ITS EXISTING CAPITAL
RESOURCES
WILL BE SUFFICIENT TO FUND OPERATIONS INTO 2021
* RUBIUS THERAPEUTICS - ON TRACK TO FILE FIRST
INVESTIGATIONAL NEW
DRUG APPLICATION FOR RTX-134 DURING Q1 OF 2019
Source text for Eikon: ID:nGNX5Ttzc6
Further company coverage: RUBY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rubius Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Apple, TCR2 Therapeutics, Silvergate Capital
Brief: Rubius Therapeutics Inc - Nasdaq Notified Co That Trading In Co's Stock Will Be Suspended Upon Opening Of Business On March 7, 2023
Brief: Rubius Therapeutics Board Of Directors Approved Plan Of Liquidation And Dissolution Of Company
Rubius Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Baidu, Boeing, Microsoft